WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
The Lynx Group | August 14, 2020
The Lynx Group (TLG) has acquired Upstream Partners in an effort to create a dynamic division catering directly to the pharmaceutical and biotech space. The ability to leverage the deep experiences and broad networks of both companies with external healthcare decision-makers and influencers together, allows the new division of TLG to provide pharmaceutical and biotech clients with thorough, market-informed perspectives needed throughout a product's life cycle. These insights are invaluable f...
Ginkgo Bioworks | August 20, 2022
Ginkgo Bioworks the leading horizontal platform for cell programming, announced the purchase of certain epidemiological data infrastructure assets from Baktus, Inc., a Delaware-based public benefit corporation. Under the terms of the deal, Ginkgo will assume ownership of proprietary datasets, modeling and analytic tools, and a software platform with the capabilities to track, model, and forecast epidemics and associated risks and impacts. Ginkgo also expects to integrate several ongoing epidemio...
CELL AND GENE THERAPY
Mission Bio | April 20, 2022
Mission Bio, Inc., a leader in high-throughput single-cell DNA and multi-omics analysis, announced today a co-marketing agreement with S2 Genomics, Inc., a leading developer of laboratory automation solutions for processing solid tissues for single-cell applications, to provide a single streamlined workflow for solid tumor applications from sample prep to analysis. Christine A. Iacobuzio-Donahue, MD, Ph.D., Director of the Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer ...
AVM Biotechnology | July 09, 2020
Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer. As COO, Rea will lead operations and direct regulatory affairs as the company conducts clinical trials and brings AVM0703 to market."I am...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE